FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385157084> ?p ?o ?g. }

• W4385157084 endingPage "110553" @default.
• W4385157084 startingPage "110553" @default.
• W4385157084 abstract "Palmoplantar pustulosis (PPP), a chronic, recurrent pustular dermatosis associated with erythema, scales, and sterile pustules on the palms and soles, is commonly encountered in dermatology clinics. Whether PPP is a variant of psoriasis or a distinct condition is still debated. Although biological agents have been successfully used to treat moderate-to-severe psoriasis, existing literature on PPP is limited to case reports or small case series. The lack of well-documented clinical studies makes it difficult to select the ideal treatment for this condition. This review aims to discuss the efficacy and safety of biological agents in PPP treatment based on randomized controlled trials with the hope of inspiring dermatologist clinicians to propose new therapeutic approaches.This review aims to obtain high-level evidence to assess the efficacy and safety of biological agents in the treatment of patients with PPP.We searched the PubMed, Embase, and Cochrane databases up to May 18, 2023, for high-quality randomized controlled trials that reported at least one adverse event after PPP treatment with biological agents in patients > 18 years of age. RevMan 5.3 software was used for the meta-analysis.Nine trials involving 799 participants were included in the analysis. We used ppPASI 75 as the primary efficacy measure. Anti-IL-23 and anti-IL-17A agents afforded 4.14-fold and 1.95-fold better outcomes than placebo treatment at weeks 16 and 12, respectively (P-value = 0.009, RR = 4.14, 95% confidence interval [CI; 1.43-11.98]; P-value = 0.02, RR = 1.95, 95% CI [1.11-3.42]). Moreover, anti-IL-23 agents at a dose of 100 mg were more effective than at 200 mg, indicating that 100 mg may be the best dose for anti-IL-23 agents. Next, we investigated the safety of biological agents for PPP treatment. The incidence of total adverse events (AEs) was 1.25 times higher for biological agents than for controls, indicating a good safety profile (RR = 1.25, P-value ＜ 0.00001, 95% CI [1.13, 1.37]). Additionally, we divided the common AEs into 16 categories and found that anti-IL-23 agents were more likely to induce infections. In conclusion, we evaluated safety and efficacy in a comprehensive comparison and found that anti-IL-23 agents conferred good clinical efficacy with a low incidence of AEs and could be recommended with caution.Only a few relevant, high-quality, randomized controlled trials were included in the study.This study showed that biological agents can be used to treat patients with PPP with good efficacy; however, AEs cannot be ignored. Multi-center, high-quality clinical studies with large sample sizes are needed to further evaluate the effects and safety of biological agents in PPP treatment." @default.
• W4385157084 created "2023-07-24" @default.
• W4385157084 creator A5004075655 @default.
• W4385157084 creator A5011075044 @default.
• W4385157084 creator A5017992615 @default.
• W4385157084 creator A5022526821 @default.
• W4385157084 creator A5071506258 @default.
• W4385157084 creator A5076922989 @default.
• W4385157084 creator A5078838888 @default.
• W4385157084 creator A5079534445 @default.
• W4385157084 creator A5083536113 @default.
• W4385157084 creator A5088593500 @default.
• W4385157084 creator A5092524675 @default.
• W4385157084 date "2023-09-01" @default.
• W4385157084 modified "2023-10-18" @default.
• W4385157084 title "Efficacy and safety of biological agents to treat patients with palmoplantar pustulosis: A systematic scoping review" @default.
• W4385157084 cites W1525199580 @default.
• W4385157084 cites W1931293371 @default.
• W4385157084 cites W2029806247 @default.
• W4385157084 cites W2045015441 @default.
• W4385157084 cites W2053528201 @default.
• W4385157084 cites W2064535395 @default.
• W4385157084 cites W2064709295 @default.
• W4385157084 cites W2095356310 @default.
• W4385157084 cites W2134833483 @default.
• W4385157084 cites W2153113150 @default.
• W4385157084 cites W2344070907 @default.
• W4385157084 cites W2408685517 @default.
• W4385157084 cites W2468433846 @default.
• W4385157084 cites W2527420241 @default.
• W4385157084 cites W2743714815 @default.
• W4385157084 cites W2762592199 @default.
• W4385157084 cites W2769138774 @default.
• W4385157084 cites W2789890489 @default.
• W4385157084 cites W2911486644 @default.
• W4385157084 cites W2955497129 @default.
• W4385157084 cites W3000072935 @default.
• W4385157084 cites W3006942965 @default.
• W4385157084 cites W3011891394 @default.
• W4385157084 cites W3040081948 @default.
• W4385157084 cites W3088231549 @default.
• W4385157084 cites W3134953187 @default.
• W4385157084 cites W3171392946 @default.
• W4385157084 cites W3195402534 @default.
• W4385157084 cites W3195538306 @default.
• W4385157084 cites W4246898697 @default.
• W4385157084 cites W4254993689 @default.
• W4385157084 cites W4256668170 @default.
• W4385157084 doi "https://doi.org/10.1016/j.intimp.2023.110553" @default.
• W4385157084 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37480749" @default.
• W4385157084 hasPublicationYear "2023" @default.
• W4385157084 type Work @default.
• W4385157084 citedByCount "0" @default.
• W4385157084 crossrefType "journal-article" @default.
• W4385157084 hasAuthorship W4385157084A5004075655 @default.
• W4385157084 hasAuthorship W4385157084A5011075044 @default.
• W4385157084 hasAuthorship W4385157084A5017992615 @default.
• W4385157084 hasAuthorship W4385157084A5022526821 @default.
• W4385157084 hasAuthorship W4385157084A5071506258 @default.
• W4385157084 hasAuthorship W4385157084A5076922989 @default.
• W4385157084 hasAuthorship W4385157084A5078838888 @default.
• W4385157084 hasAuthorship W4385157084A5079534445 @default.
• W4385157084 hasAuthorship W4385157084A5083536113 @default.
• W4385157084 hasAuthorship W4385157084A5088593500 @default.
• W4385157084 hasAuthorship W4385157084A5092524675 @default.
• W4385157084 hasConcept C126322002 @default.
• W4385157084 hasConcept C142724271 @default.
• W4385157084 hasConcept C16005928 @default.
• W4385157084 hasConcept C168563851 @default.
• W4385157084 hasConcept C17744445 @default.
• W4385157084 hasConcept C177713679 @default.
• W4385157084 hasConcept C197934379 @default.
• W4385157084 hasConcept C199539241 @default.
• W4385157084 hasConcept C204787440 @default.
• W4385157084 hasConcept C27081682 @default.
• W4385157084 hasConcept C2779473830 @default.
• W4385157084 hasConcept C2780564577 @default.
• W4385157084 hasConcept C2909516574 @default.
• W4385157084 hasConcept C71924100 @default.
• W4385157084 hasConcept C95190672 @default.
• W4385157084 hasConceptScore W4385157084C126322002 @default.
• W4385157084 hasConceptScore W4385157084C142724271 @default.
• W4385157084 hasConceptScore W4385157084C16005928 @default.
• W4385157084 hasConceptScore W4385157084C168563851 @default.
• W4385157084 hasConceptScore W4385157084C17744445 @default.
• W4385157084 hasConceptScore W4385157084C177713679 @default.
• W4385157084 hasConceptScore W4385157084C197934379 @default.
• W4385157084 hasConceptScore W4385157084C199539241 @default.
• W4385157084 hasConceptScore W4385157084C204787440 @default.
• W4385157084 hasConceptScore W4385157084C27081682 @default.
• W4385157084 hasConceptScore W4385157084C2779473830 @default.
• W4385157084 hasConceptScore W4385157084C2780564577 @default.
• W4385157084 hasConceptScore W4385157084C2909516574 @default.
• W4385157084 hasConceptScore W4385157084C71924100 @default.
• W4385157084 hasConceptScore W4385157084C95190672 @default.
• W4385157084 hasLocation W43851570841 @default.
• W4385157084 hasLocation W43851570842 @default.
• W4385157084 hasOpenAccess W4385157084 @default.

• next